...
首页> 外文期刊>Cellular Physiology and Biochemistry >Neuregulin-1 Promotes Myocardial Angiogenesis in the Rat Model of Diabetic Cardiomyopathy
【24h】

Neuregulin-1 Promotes Myocardial Angiogenesis in the Rat Model of Diabetic Cardiomyopathy

机译:Neuregulin-1促进糖尿病性心肌病大鼠模型中的心肌血管生成

获取原文

摘要

Background/Aims Microvascular insufficiency takes a critical role in the development of diabetic cardiomyopathy (DCM). So this study was designed to investigate the effects of Neuregulin-1 (NRG-1) treatment on myocardial angiogenesis and the changes of VEGF/Flk1 and Ang-1/Tie-2 signaling in the rat model of DCM. Methods Diabetic rats were induced by a single intraperitoneal injection of Streptozotocin. 12 weeks after the diabetes induction, the rats with NRG-1 treatment were treated with tail vein injection of NRG-1 at the dose of 10µg/kg/d for consecutive 10 days. Cardiac function was assessed using catheter MPA cardiac function analysis system. Myocardial blood flow (MBF) was assessed with stable-isotope labeled microspheres. Capillary density was measured by CD31 immunohistochemistry. The protein expression and receptors phosphorylation were assessed using western blot. Results Left ventricular function, capillary density and MBF were significantly reduced in DCM group when compared with those in the control group (P< 0.01, P< 0.01 and P< 0.05 respectively). Left ventricular function and capillary density were significantly increased in NRG-1 treatment group when compared with those in the DCM group (P< 0.05 and P< 0.05 respectively). The expression of VEGF and Ang-1 and the phosphorylation of Flk1 and Tie-1 were significantly decreased in DCM group as compared with those in the control group. However, those in the NRG-1 treatment group were significantly increased as compared with those in the DCM group. In vitro, NRG-1 treatment increased significantly the expression of VEGF and Ang-1 in human coronary artery smooth muscle cells. Conclusions NRG-1 can increase the myocardial angiogenesis of DCM, probably via the direct effects of NRG-1 and via the increasing expression of VEGF and Ang-1. These findings may contribute to developing a novel approach to reverse the impaired angiogenic responses in diabetes or coronary artery disease.
机译:背景/目的微血管功能不全在糖尿病性心肌病(DCM)的发展中起着至关重要的作用。因此,本研究旨在研究神经调节蛋白-1(NRG-1)治疗对DCM大鼠模型中心肌血管生成的影响以及VEGF / Flk1和Ang-1 / Tie-2信号的变化。方法腹腔注射链脲佐菌素诱导糖尿病大鼠。诱导糖尿病后12周,连续10天以10μg/ kg / d的剂量将NRG-1尾静脉注射NRG-1处理的大鼠。使用导管MPA心脏功能分析系统评估心脏功能。用稳定同位素标记的微球评估心肌血流量(MBF)。通过CD31免疫组织化学测量毛细血管密度。使用蛋白质印迹法评估蛋白质表达和受体磷酸化。结果与对照组相比,DCM组左心室功能,毛细血管密度和MBF显着降低(分别为P< 0.01,P< 0.01和P< 0.05)。与DCM组相比,NRG-1治疗组的左心室功能和毛细血管密度显着增加(分别为P< 0.05和P< 0.05)。与对照组相比,DCM组VEGF和Ang-1的表达以及Flk1和Tie-1的磷酸化明显降低。但是,与DCM组相比,NRG-1治疗组的患者显着增加。在体外,NRG-1处理可显着增加人冠状动脉平滑肌细胞中VEGF和Ang-1的表达。结论NRG-1可能通过NRG-1的直接作用以及通过增加VEGF和Ang-1的表达来增加DCM的心肌血管生成。这些发现可能有助于开发一种新颖的方法来逆转糖尿病或冠状动脉疾病中受损的血管生成反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号